SNOA earnings analysis
What we found in SNOA's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Sonoma Pharmaceuticals (SNOA) reported total revenue of $19.5 million for the fiscal year ending March 31, 2026, a 37% increase compared to $14.3 million in the previous year. The gross margin held steady at 38%, and the net loss narrowed to $3.2 million, down from $3.5 million a year earlier. The company has faced ongoing operational challenges, and its future profitability hinges on successful collaborations and product commercialization in both domestic and international markets.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 37%
- Total revenue increased to $19.5 million in FY2026 from $14.3 million in FY2025.
- Stable Gross Margin
- Gross margin remained consistent at 38% for both FY2025 and FY2026.
- Narrowed Net Loss
- Net loss reduced to $3.2 million in FY2026 from $3.5 million in FY2025.
- Increased U.S. Sales
- U.S. revenue grew to $5.7 million, up 117% year-over-year from $2.6 million.
- Strong International Performance
- Revenue from Rest of World increased 92%, contributing to overall growth.
- Successful Capital Raise
- In April 2026, SNOA raised $3.5 million from a public offering, enhancing liquidity.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Dependency on Key Customers
- For FY2026, Customer C accounted for 15% of net revenues, indicating reliance on a few key customers.
- High Intercompany Debt
- The Mexican subsidiary owes approximately $12.3 million in principal with potential tax liabilities exceeding $16.5 million.
- Regulatory Approval Risks
- Future product approvals depend on compliance with varying international regulations, which are costly and time-consuming.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.89
- Gross margin
- 38%
- Segment
- Human Care
- Segment
- Animal Care
What they said about what is next.
Annual outlook deferred to earnings press release / call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · August 7, 2025
- Sonoma reported revenue of $4,015,000 for the quarter (up $624,000 or ~18% YoY) with gross profit of $1,464,000 and net loss of $1,241,000 (EPS $(0.76)). Operating loss improved to $(1,095,000) (operating margin -27.3%)…
- 10-Q · November 7, 2024
- Sonoma reported quarterly revenue of $3,579,000 (up from $2,731,000 a year earlier, +$848,000) and improved operating results: gross profit was $1,361,000 and loss from operations narrowed to $(850,000) from…
- 10-K · June 17, 2024
- Sonoma positions itself as a specialist developer and manufacturer of stabilized hypochlorous acid (HOCl) products across dermatology, wound care, eye/oral/nasal care, podiatry, animal health and surface disinfectants,…
- 10-Q · February 8, 2024
- Sonoma reported quarterly revenue of $3,138,000 (up from $2,944,000 year‑ago) with gross profit of $1,460,000 and a substantially narrower operating loss of $(844,000) vs $(1,834,000) prior year. Net loss improved to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SNOA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever